For clinicians
A neutral reference for prescribers
Patients increasingly arrive asking about peptides sold online or offered by telehealth clinics, and most of what is written about them is written to sell them. These pages report what a prescriber needs to know before that conversation, for every compound in our regulatory tracker: regulatory and compounding status, anti-doping status, the quality of the human evidence, and what FDA itself has said. They never suggest a dose, a protocol or a source.
What every page contains
- Regulatory status, generated, not typed. FDA approval, 503A and 503B status, FDA advisory committee review and WADA status for 2026 and 2027, drawn from our regulatory tracker by the same code that writes it, with the date each row was reviewed.
- The evidence grade from our encyclopedia, defined on the methodology page.
- What FDA has said, in FDA's terms: for approved drugs, the label's boxed warning and the headings of its Warnings and Precautions section, with a link to the full prescribing information; for compounds FDA reviewed for compounding, its findings; for the rest, FDA's own published words on their risks, quoted exactly, or a plain statement that FDA has published none we can report.
- Monitoring, honestly: for an approved drug, where in the label monitoring is set out; for a compound with no approved label, the gaps FDA identified rather than an invented schedule.
What no page contains
Doses, regimens, cycle lengths, stacks or sources. A reference is useful to a prescriber only if it cannot be mistaken for a protocol. For approved drugs the label is the source of dosing, and these pages link it rather than copy it.
Reviewed by FDA's compounding committee in July 2026 (7)
The seven compounds FDA's Pharmacy Compounding Advisory Committee reviewed on July 23–24, 2026, which is why compounding questions about them are live.
| Compound | US status | WADA 2027 | Evidence |
|---|---|---|---|
| BPC-157 | Not compoundable; PCAC recommended it 8–6 (Jul 2026), FDA has not acted | Prohibited (S0) | Low |
| Emideltide (DSIP) | Not compoundable; PCAC voted against it 6–7 (Jul 2026) | Prohibited (S0 catch-all) | Low |
| Epitalon | Not compoundable; PCAC recommended it 7–4 or 7–5 (Jul 2026), FDA has not acted | Prohibited (S0 catch-all) | Low |
| KPV | Not compoundable; PCAC recommended it 8–6 (Jul 2026), FDA has not acted | Prohibited (S0 catch-all) | Low |
| MOTS-c | Not compoundable; PCAC recommended it 7–5 (Jul 2026), FDA has not acted | Prohibited (S4.4.1) | Low |
| Semax | Not compoundable; PCAC recommended it 8–5 (Jul 2026), FDA has not acted | Unsettled (S0 may apply) | Medium |
| TB-500 | Not compoundable; PCAC recommended it 8–6 (Jul 2026), FDA has not acted | Prohibited (S2.3) | Low |
FDA-approved (15)
Approved drugs. Each page lists its label's boxed warning and Warnings and Precautions headings, and links the full prescribing information.
| Compound | US status | WADA 2027 | Evidence |
|---|---|---|---|
| Bremelanotide (PT-141) | Rx (FDA-approved as Vyleesi) | Not on the 2027 List | High |
| Dulaglutide | Rx (FDA-approved as Trulicity) | Not on the 2027 List | High |
| Exenatide | Rx (FDA-approved) | Not on the 2027 List | High |
| hCG | Rx (FDA-approved) | Prohibited (S2.2.1) | High |
| IGF-1 (mecasermin) | Rx (FDA-approved as Increlex) | Prohibited (S2.3) | High |
| Leuprolide | Rx (FDA-approved as Lupron) | Prohibited (S2.2.1) | High |
| Liraglutide | Rx (FDA-approved) | Not on the 2027 List | High |
| Octreotide | Rx (FDA-approved as Sandostatin) | Not on the 2027 List | High |
| Orforglipron | Rx (FDA-approved as Foundayo) | Not on the 2027 List | Medium |
| Semaglutide | Rx (FDA-approved) | Not on the 2027 List | High |
| Somatropin | Rx (FDA-approved as multiple) | Prohibited (S2.2.3) | High |
| SS-31 (elamipretide) | Rx (FDA-approved as Forzinity) | Not on the 2027 List | High |
| Teriparatide | Rx (FDA-approved as Forteo) | Not on the 2027 List | High |
| Tesamorelin | Rx (FDA-approved as Egrifta) | Prohibited (S2.2.4) | High |
| Tirzepatide | Rx (FDA-approved) | Not on the 2027 List | High |
Investigational (3)
In clinical trials and not approved.
| Compound | US status | WADA 2027 | Evidence |
|---|---|---|---|
| CagriSema | Investigational (clinical trials only) | Prohibited (S0 catch-all) | High |
| Retatrutide | Investigational (clinical trials only) | Prohibited (S0 catch-all) | Medium |
| Survodutide | Investigational (clinical trials only) | Prohibited (S0 catch-all) | High |
Not approved, encountered outside approval (19)
Compounds patients meet online or through clinics. Where FDA has said something about their risks in compounding, the page quotes it exactly.
| Compound | US status | WADA 2027 | Evidence |
|---|---|---|---|
| AOD-9604 | Not compoundable (nomination withdrawn; on no FDA list) | Prohibited (S2.2.3) | Medium |
| Cathelicidin (LL-37) | Not compoundable; PCAC review due by Feb 2027 | Prohibited (S0 catch-all) | Low |
| Cerebrolysin | Not compoundable (nomination withdrawn; on no FDA list) | Unsettled (S0 may apply) | High |
| CJC-1295 | Not compoundable (nomination withdrawn; on no FDA list) | Prohibited (S2.2.4) | Medium |
| Dihexa | Not compoundable; PCAC review due by Feb 2027 | Prohibited (S0 catch-all) | Low |
| GHK-Cu (injectable) | Injectable: not compoundable; PCAC review due by Feb 2027 | Prohibited (S0 catch-all) | Low |
| GHRP-6 | Category 3 (nominated without adequate support): not compoundable; 503B Category 2 | Prohibited (S2.2.4) | Medium |
| Hexarelin | Not compoundable (nomination withdrawn; on no FDA list) | Prohibited (S2.2.4) | Medium |
| Ipamorelin | Not compoundable (nomination withdrawn; on no FDA list); 503B Category 2 | Prohibited (S2.2.4) | Medium |
| Melanotan II | Not compoundable; PCAC review due by Feb 2027 | Prohibited (S0 catch-all) | Low |
| MK-677 (ibutamoren) | Category 2 (safety risks): not compoundable | Prohibited (S2.2.4) | Medium |
| Noopept | Not compoundable (nomination withdrawn; on no FDA list) | Unsettled (S0 may apply) | Medium |
| PEG-MGF | Not compoundable; PCAC review due by Feb 2027 | Prohibited (S2.3) | Low |
| Pralmorelin (GHRP-2) | Category 3 (nominated without adequate support): not compoundable; 503B Category 2 | Prohibited (S2.2.4) | High |
| Selank | Not compoundable (nomination withdrawn; on no FDA list) | Unsettled (S0 may apply) | Medium |
| Sermorelin | Not compoundable (nomination withdrawn; on no FDA list) | Prohibited (S2.2.4) | Medium |
| Tesofensine | Not compoundable (nomination withdrawn; on no FDA list) | Prohibited (S6.B) | Medium |
| Thymopentin | Not compoundable (nomination withdrawn; on no FDA list) | Unsettled (S0 may apply) | Medium |
| Thymosin α-1 | Not compoundable (nomination withdrawn; on no FDA list) | Unsettled (S0 may apply) | High |
How these pages stay current
Each page is rebuilt from the tracker, the labels and FDA's lists, so when FDA acts on a nomination, revises a label or WADA changes its list, the pages change with them. The review date on each page is the date its tracker row was last checked against FDA's and WADA's own documents.
These pages are a reference for qualified professionals. They are not medical advice and do not recommend any treatment.